Biomarkers of Tobacco Carcinogenesis in Diverse Populations: Challenges and Opportunities

被引:3
|
作者
Etemadi, Arash [1 ,2 ]
Abnet, Christian C. [1 ]
Dawsey, Sanford M. [1 ]
Freedman, Neal D. [1 ]
机构
[1] Natl Canc Inst NCI, Div Canc Epidemiol & Genet, Metab Epidemiol Branch, NIH, Bethesda, MD USA
[2] NCI, 9609 Med Ctr Dr,RM 6E340, Bethesda, MD 20892 USA
关键词
SMOKING; RISK;
D O I
10.1158/1055-9965.EPI-22-1289
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Biomarkers can provide distinct information about cancer risk factors in populations from diverse ancestries and with different exposure patterns by measuring the internal dose of carcinogens. While similar environmental exposures can lead to different cancer risks across racial or ethnic groups, seemingly different exposures can cause the same cancers because they produce the same biomarkers in the body. Smoke-related biomarkers are among the most commonly studied biomarkers in relation to cancer, and they include tobacco-specific biomarkers (nicotine metabolites and tobacco-specific nitrosamines) and biomarkers which can result from exposure to tobacco and non-tobacco pollutants (polycyclic aromatic hydrocarbon and volatile organic compounds). Biomonitoring is superior to self-reported exposure assessment because it is less prone to information and recall biases. However, biomarkers generally reflect recent exposure determined by their metabolism and half-life and how they are stored in and excreted from the body. Many biomarkers are correlated because the sources of exposure usually contain several carcinogens at the same time, making it difficult to identify specific chemicals which lead to cancer. Despite these challenges, biomarkers will continue to be essential to cancer research. Prospective studies, with detailed exposure assessment and large sample sizes from diverse backgrounds, along with studies designed to enrich the methodology of biomarker research are the necessary steps in that direction. See related article by Cigan et al., p. 306
引用
收藏
页码:289 / 291
页数:3
相关论文
共 50 条
  • [41] Extracellular vesicles as circulating cancer biomarkers: opportunities and challenges
    Lane, R. E.
    Korbie, D.
    Hill, M. M.
    Trau, M.
    CLINICAL AND TRANSLATIONAL MEDICINE, 2018, 7
  • [42] Challenges and opportunities for small and medium-sized businesses (SMEs) arising from ethnically, racially and religiously diverse populations
    Lindgreen, Adam
    Hingley, Martin K.
    ENTREPRENEURSHIP AND REGIONAL DEVELOPMENT, 2010, 22 (01): : 1 - 4
  • [43] Immunotherapy biomarkers for HCC: contemporary challenges and emerging opportunities
    Kwee, Sandi
    Chen, Xin
    HEPATOMA RESEARCH, 2022, 8
  • [44] Safety biomarkers: Opportunities and challenges in drug discovery and development
    Schuppe-Koistinen, Ina
    TOXICOLOGY LETTERS, 2012, 211 : S9 - S9
  • [45] ACCELERATING BEHAVIORAL HEALTH RESEARCH WITH BIOMARKERS: CHALLENGES AND OPPORTUNITIES
    Jallo, Nancy
    Kinser, Patricia A.
    Sargent, Lana
    ANNALS OF BEHAVIORAL MEDICINE, 2020, 54 : S140 - S140
  • [46] Disease Biomarkers for Precision Medicine:Challenges and Future Opportunities
    Edwin Wang
    William C.S.Cho
    S.C.Cesar Wong
    Siqi Liu
    Genomics,Proteomics & Bioinformatics, 2017, (02) : 57 - 58
  • [47] Predictive biomarkers for immunotherapy in lung cancer: Opportunities and challenges
    Schalper, Kurt
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (02) : S12 - S13
  • [48] Enhancing microbiome-based biomarkers: challenges and opportunities
    Gopal, Rajesh Kanna
    Ganesh, Pitchaipillai Sankar
    Pathoor, Naji Naseef
    Viswanathan, Akshaya
    LANCET MICROBE, 2025, 6 (03):
  • [49] Challenges and Opportunities for Biomarkers of Clinical Response to AHSCT in Autoimmunity
    Harris, Kristina M.
    Lu, Tingting
    Lim, Noha
    Turka, Laurence A.
    FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [50] PREDICTIVE BIOMARKERS IN EARLY DRUG DEVELOPMENT CHALLENGES AND OPPORTUNITIES
    Tolcher, A. W.
    ANNALS OF ONCOLOGY, 2012, 23 : 10 - 10